Not rendering correctly? View this email as a web page here.
Grail's NHS Trial Failed To Meet Its Primary Endpoint, & More
facebook-icon-white
x
instagram-icon-white
ARK Invest logo

ARK • Disrupt

It's Your weekly innovation newsletter

It's Monday, February 23, 2026. Please enjoy ARK's weekly newsletter curated by our thematic research team and designed to keep you engaged with disruptive innovation.

Grail's NHS Trial Failed To Meet Its Primary Endpoint

ARK Invest_Headshot_Ovid-Amadi_668x668

By Ovid Amadi, PhD | @Ovid_ARK
Multiomics Portfolio Manager & Director of Research

The FDA's Shift To One Pivotal Trial Could Transform The Economics Of Drug Development

ARK Invest_Headshot_Shea-Wihlborg_668x668

By Shea Wihlborg | @Shea_ARK
Research Analyst

 

 

 

 

 

 

WATCH

Chinese Humanoids Are Prolific But Not Useful, Yet

ARK-Log-Icon-Black-1000px (2)

By Akaash TK & Tasha Keeney, CFA | @ARKInvest
Autonomous Technology & Robotics Team

Copyright © 2026 ARK Investment Management LLC, All rights reserved.

200 Central Avenue,

St. Petersburg, FL 33701 United States

You received this email because you are subscribed to Research Newsletters from ARK Investment Management LLC.

Unsubscribe from ARK emails or choose the types of emails you want to receive. Unsubscribe from all.